Today's guest post comes from Sahil Naik, Chief Growth Officer at PHIL Inc.
Sahil examines how direct-to-patient programs may be able to support affordability and patient engagement throughout the treatment journey. He highlights integrated access pathways and targeted patient engagement as opportunities for manufacturers to evolve their direct-to-patient strategies.
To explore PHIL's research on direct-to-patient trends, download their report The DTP Breakthrough: A Deep Dive on Pharma’s Direct-to-Patient Next Generation.
Read on for Sahil's insights.
The Direct-to-Patient Opportunity: Evolving Pharma’s DTP Strategy for Lasting Patient Engagement
By Sahil Naik, Chief Growth Officer, PHIL Inc.
Direct-to-patient (DTP) has matured from an emerging channel into an established access infrastructure. New research from PHIL reveals 76% of U.S. life sciences leaders now designate DTP as a "mission critical" or "very important" strategic priority today, with “mission critical” sentiment growing by 20% in the next 12 months. However, side-by-side analysis of independent research findings from the past year across patient expectations, healthcare provider perspectives, and manufacturer priorities reveals structural disconnects that may be limiting the potential reach and impact of these programs. To transform direct-to-patient into a core commercial function, brand leaders must evolve their access architecture to drive lasting patient engagement.
The Affordability Opportunity: Evolving from Patient-Navigated Choice to Integrated Access Ecosystem
Affordability is the primary determinant of patient engagement in DTP programs. For patients, "lower cost" is the number one driver for engaging with a DTP program, carrying more than double the ranked influence of the next most influential factors, speed of access and quality of care. 65% report they will use a DTP program if it offers the lowest medication cost, and 96% of patients want price transparency before committing to a medication.
Healthcare providers validate this friction at the point of prescribing. One in two HCPs lack confidence that patients can navigate out-of-pocket (OOP) costs on their own. Consequently, HCPs identify medications not covered by insurance and high OOP costs as the top reasons for patient abandonment. Ensuring patients receive the lowest price is the #1 factor HCPs consider when prescribing to a digital channel.
Pharma has made significant strides in improving affordability through direct-to-patient initiatives. 63% of established DTP programs use hybrid models that dynamically route patients to the most affordable pathway between cash pay and coverage. Pharma leaders currently rank offering multiple affordability pathways, flexible intake options, and speed of access as their top three focus areas for addressing patient needs in these programs.
With hybrid pathways as the baseline, the next opportunity involves moving beyond offering patients the choice between multiple access pathways and towards dynamically guiding them to the best outcome through a single, integrated access ecosystem. In many DTP programs today, patients are asked to decide whether to use insurance or pay cash, which telehealth provider to use, and which pharmacy to fill at, often before they can see what each option costs. The opportunity is for pharma’s DTP programs to act as a single, digital front door that centralizes every available access pathway for each patient, including copay and coverage support, available discounts, patient assistance, education materials, and practitioner support, connecting patients to an optimal outcome. With this centralized approach, manufacturer programs can become a trusted source of truth for patients, delivering the consistent, convenient, and affordable access experience they expect.
The Experience Opportunity: Driving Targeted Patient Engagement through e-Commerce-Style Awareness Generation
Pharma teams invested $10 billion in ads in 2025, yet 27% of all written prescriptions go unfilled. When forced to access medication through rigid channels, patients are less likely to start and stay on their prescribed therapies. 32% of patients prefer a fully online or hybrid experience, and 1 in 3 will abandon a medication if they cannot use their preferred access model. In digital access experiences, 95% of patients want DTP programs to mirror e-commerce.
Pharma leaders recognize the need for digital infrastructure, with 77% of manufacturers today having established or emerging DTP programs to expand access experiences. In these initiatives, brands remain focused on driving topline awareness, with leaders citing patient awareness as a primary barrier to greater program impact, and marketing and awareness building as a top three investment priority in the next 12 months.
In a direct-to-patient world, pharma leaders have an opportunity to embrace e-commerce-style performance marketing, leveraging full-funnel patient journey data to prioritize investments that drive awareness among patients that are most likely to engage with and benefit from DTP programs. Traditionally, marketing performance data and patient journey data have been siloed and analyzed separately, making it difficult for brand teams to meaningfully improve how they drive awareness and engagement through targeted campaigns. Direct-to-patient programs give brand leaders the opportunity to track patients throughout the entire access journey, from ad through adherence, and leverage this data to turn interest and awareness into meaningful engagement. The outcome is a hyper-targeted experience that connects the right patients to the programs tailored to their needs and preferences.
Evolving Pharma’s DTP Strategy for Lasting Patient Engagement
To embrace these opportunities, 95% of manufacturers plan to partner with DTP solution providers rather than build capabilities in-house. In evaluating partners, commercial leaders are prioritizing end-to-end patient journey platforms with the flexibility to evolve and that offer fully custom, brand-tailored programs. Best-in-class partners elevate these capabilities into a true strategic partnership, acting as an extension of the brand team by translating full-funnel insights into strategic program improvements. Successful partnerships will evolve direct-to-patient into a core commercial function, working together to drive program improvements that result in lasting patient engagement and sustainable brand performance.
PHIL connects pharma leaders to data-driven insights. Download the full research report, The DTP Breakthrough:A Deep Dive on Pharma’s Direct-to-Patient Next Generation to discover new and emerging trends in direct-to-patient.
Sponsored guest posts are bylined articles that are screened by Drug Channels to ensure a topical relevance to our exclusive audience. The content of Sponsored Posts does not necessarily reflect the views of HMP Omnimedia, LLC, Drug Channels Institute, its parent company, or any of its employees. To find out how you can publish a guest post on Drug Channels, please contact Marie Caldwell (mcaldwell@hmpglobal.com).




